...
首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines
【24h】

Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines

机译:RAF-1激酶抑制蛋白的下调作为肝细胞癌中的索拉非苯基抗性机制

获取原文
获取原文并翻译 | 示例

摘要

Although sorafenib enhances overall survival, sorafenib resistance has been reported to be a significant limiting factor for improved prognosis in patients with hepatocellular carcinoma (HCC). Therefore, it is important to identify the mechanism of sorafenib resistance. This study aimed to identify the causative factor of sorafenib resistance and suggest methods for overcoming it.
机译:尽管索拉非尼可提高总体生存率,但据报道,索拉非尼耐药性是改善肝细胞癌(HCC)患者预后的一个重要限制因素。因此,确定索拉非尼耐药性的机制非常重要。本研究旨在确定索拉非尼耐药性的原因,并提出克服该耐药性的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号